spini4
Bluelighter
- Joined
- Nov 18, 2003
- Messages
- 795
Oct 22 (Reuters) - Pfizer Inc said it would continue developing the abuse-resistant painkiller made by its partner Pain Therapeutics Inc and would conduct new clinical trials to address questions raised by the U.S. regulator regarding the drug.
Pain Therapeutics shares jumped 22 percent in premarket trading.
The drug, Remoxy, has been rejected twice by the U.S. Food and Drug Administration due to concerns about its manufacturing process and chemical composition.
Remoxy was developed using the abuse-resistant technology of Durect Corp, whose shares rose 7 percent before the bell.
Read more at: http://in.mobile.reuters.com/article/idINL3N0IC3CQ20131022?irpc=932
Pain Therapeutics shares jumped 22 percent in premarket trading.
The drug, Remoxy, has been rejected twice by the U.S. Food and Drug Administration due to concerns about its manufacturing process and chemical composition.
Remoxy was developed using the abuse-resistant technology of Durect Corp, whose shares rose 7 percent before the bell.
Read more at: http://in.mobile.reuters.com/article/idINL3N0IC3CQ20131022?irpc=932